Foren & Soziale Netzwerke zur MODERNA Aktie

 

NASDAQ:MRNA — major short squeeze still going on. Here's how I think this will play out. ? #MRNA #Moderna #ShortSqueeze #Stocks #Trading #StockMarket #TechnicalAnalysis #PriceAction #DayTrading #Investing

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna's recent rally is driven by two strong clinical milestones: the personalized mRNA melanoma vaccine developed with Merck hit its Phase 3 goals, and the seasonal flu shot (mFLUSIVA) received FDA approval. Analysts are treating the melanoma result as a landmark validation of Moderna's oncology pipeline, and price targets have been revised sharply higher. The technical picture confirms the fundamental story. The broader trend structure supports further upside expansion toward the 250–310 resistance zone over the coming months. Chart: https://www.tradingview.com/x/4xAYWVMR/ We keep this scenario active as long as price holds above the 117–103 support area. We plan to enter once a clean risk/reward setup appears.

Short-Term Outlook After an almost 200% move in a stock in a single day, making a definitive prediction about whether the bullish move will see follow-through—or whether a short-term top is already in place and an immediate corrective wave will follow—would be little more than fortune-telling. History was made yesterday; let's call it what it is. We're pleased to have correctly anticipated the move—not to this extent, obviously, but the direction and its imminence were clear. For short-term targets, however, we'll need to step back and closely monitor the market's reaction over the next few trading sessions. Long-Term Outlook The weekly chart suggests the stock should see significant long-term gains and eventually break through resistance at $497.49, which is the current all-time high.

Moderna shares traded mostly sideways over the past week, but today we're seeing renewed upward movement. Our primary view remains that MRNA is likely to see further declines in the near term. After a low well above support at $22.32, however, a recovery should unfold, pushing the stock up to and above resistance at $85.60. If the stock were to fall below support at $22.32 in the near future, we would expect to see a lower low before the anticipated upward move resumes (probability: 20%).

https://www.tradingview.com/x/gmayCOKe/ After entering **PANW**, I continued monitoring several other stocks that had already caught my attention. A number of them were demonstrating strong relative strength and, from my perspective, signs of sustained institutional participation. Among those names, **MRNA** was the next asset to present a valid entry according to my trading plan. The signal appeared very close to the market close, and my order was filled in the final minutes of the session. Because of the timing, I didn't have the opportunity to reduce the trade's risk by moving my stop-loss to **break-even** before the market closed. As I write this before today's opening, MRNA is trading **higher in the pre-market**. I don't interpret that as a prediction of what will happen next, nor do I assume the trade will become profitable because of it. What matters to me is much simpler. If the opening provides enough strength, I'll have the opportunity to move my stop-loss to **break-even**, making the posi

der online Ausgabe nachlesbar -eintracht67

Ein lokaler Ausbruch des Hantavirus auf einem Kreuzfahrtschiff treibt die Moderna-Aktie (MRNA) an. https://traderzeitung.de/boerse/hot-news/moderna-im-hantavirus-fieber-zwischen-spekulativem-kurssprung-und-hart-167994.html -micha1

Moderna Inc Aktie (US60770K1079): Quartalsumsatz deutlich über Guidance, Aktie im AufwindDie Aktie von Moderna Inc (ISIN: US60770K1079, Ticker: MRNA) notiert am 08.05.2026 auf dem US-amerikanischen Markt bei rund 48,70 US-Dollar ... -micha1

Medienberichten zufolge arbeitet Moderna seit dem September 2023 mit der Korea University an einem Hantavirus-Impfstoff. Laut The Hill befindet sich die Forschung noch in einem frühen Stadium. "Moderna hat in Zusammenarbeit mit dem U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) präklinische Forschungen zu Hantaviren durchgeführt, was die anhaltenden regionalen Auswirkungen dieser Krankheitserreger widerspiegelt“, zitiert die US-amerikanische Zeitung einen Unternehmenssprecher.https://de.investing.com/news/stock-market-news/hantavirusforschung-treibt-modernaaktie-um-16--an-93CH-3472484 -micha1

Kursziel: -

Kursziel: -

Kursziel: 58.3326 €

Kursziel: 60.0 €

Kursziel: -

Kursziel: -

i published this setup on 15.1.26, before this break, we reached the target and even more, 43% since i published it 11 days ago. SUCCEEDED congrats who took it. I would place a stop on ATR or consider taking profit for now

Kursziel: -

MRNA looks like its doing a bearish to bullish setup, it formed a cup and handle and broke a major resistance area, and went above SMA 150 again. Disclaimer: not a financial advice trade at your own risk

Kursziel: -